Capturing a virus while it catches its breath.
The four serotypes of dengue virus present a formidable challenge for the development of efficacious human vaccines. Cockburn and colleagues, in this issue of Structure, describe the structural basis of a cross-reactive neutralizing antibody, providing greater insight into immune protection and pathogenesis.
Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD 20892, USA. piersontc@mail.nih.gov
Theodore C
TC
Pierson
Richard J
RJ
Kuhn
D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000737:chemistry*; D057134:Antibodies, Neutralizing / Q000737:chemistry*; D000998:Antiviral Agents / Q000737:chemistry*; D003716:Dengue Virus / Q000276:immunology*; D006801:Humans; D014759:Viral Envelope Proteins / Q000737:chemistry*
D058846:Antibodies, Monoclonal, Murine-Derived; D057134:Antibodies, Neutralizing; D000998:Antiviral Agents; D014759:Viral Envelope Proteins